EUVIMEDEUVIMED entdecken
Crossref

The role of immune cells in resistance to oncolytic viral therapy

Prathibha Ambegoda, Hsiu-Chuan Wei, Sophia R-J Jang

Mathematical Biosciences and Engineering · 2024

DOI: 10.3934/mbe.2024261 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mathematical Biosciences and Engineering, 2024. Verfasst von Prathibha Ambegoda und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mathematics & Statistics, Texas Tech University, Lubbock, TX, USA. Hauptthemen laut MEDLINE: Oncolytic Virotherapy, Neoplasms, Oncolytic Viruses, Computer Simulation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 88 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resistance to treatment poses a major challenge for cancer therapy, and oncoviral treatment encounters the issue of viral resistance as well. In this investigation, we introduce deterministic differential equation models to explore the effect of resistance on oncolytic viral therapy. Specifically, we classify tumor cells into resistant, sensitive, or infected with respect to oncolytic viruses for our analysis. Immune cells can eliminate both tumor cells and viruses. Our research shows that the introduction of immune cells into the tumor-virus interaction prevents all tumor cells from becoming resistant in the absence of conversion from resistance to sensitivity, given that the proliferation rate of immune cells exceeds their death rate. The inclusion of immune cells leads to an additional virus-free equilibrium when the immune cell recruitment rate is sufficiently high. The total tumor burden at this virus-free equilibrium is smaller than that at the virus-free and immune-free equilibrium. Therefore, immune cells are capable of reducing the tumor load under the condition of sufficient immune strength. Numerical investigations reveal that the virus transmission rate and parameters related to the immune response significantly impact treatment outcomes. However, monotherapy alone is insufficient for eradicating tumor cells, necessitating the implementation of additional therapies. Further numerical simulation shows that combination therapy with chimeric antigen receptor (CAR T-cell) therapy can enhance the success of treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oncolytic VirotherapyNeoplasmsOncolytic VirusesComputer SimulationHumansAnimalsTumor BurdenCell Proliferation

Stichwörter der Autor:innen

effector cellshopf bifurcationoncolytic viral therapyresistance

Autor:innen und Institutionen

  • Department of Mathematics & Statistics, Texas Tech University, Lubbock, TX, USA.
  • Department of Applied Mathematics, Feng Chia University, Taichung, Taiwan.

Zitieren

APA

Ambegoda, P., Wei, H. C., & Jang, S. R. (2024). The role of immune cells in resistance to oncolytic viral therapy. Mathematical Biosciences and Engineering. https://doi.org/10.3934/mbe.2024261

Vancouver

Ambegoda P, Wei HC, Jang SR. The role of immune cells in resistance to oncolytic viral therapy. Mathematical Biosciences and Engineering. 2024. doi:10.3934/mbe.2024261

BibTeX
@article{Ambegoda2024,
  author = {Ambegoda, Prathibha and Wei, Hsiu-Chuan and Jang, Sophia R-J},
  title = {The role of immune cells in resistance to oncolytic viral therapy},
  journal = {Mathematical Biosciences and Engineering},
  year = {2024},
  doi = {10.3934/mbe.2024261}
}
Kostenlos starten →